Aidan King, MBA, CFA
Managing Partner & Co-Founder, Fountain Healthcare Partners – Board member
Aidan, qualified by training as a pharmacist from Trinity College Dublin, enjoys the challenge presented by investing in a rapidly changing life science market. Aidan started his industry career at Elan in pharmaceutical strategic marketing before moving to New York to work in Elan’s corporate venture capital group, where investments included Quadrant Healthcare (acquired by Elan, 2000), Atrix laboratories (acquired by QLT, 2004), Idun Pharmaceuticals (acquired by Pfizer, 2005) and Zealand Pharmaceuticals (IPO, 2010).
Aidan primarily focuses on US investments, marketing and fund raising and he currently sits on the boards of Xylocor Therapeutics and Corteria Pharmaceuticals. Previously, he was the firm’s representative on the boards of Syndesi Therapeutics (acquired by Abbvie, 2022), Civitas Therapeutics (acquired by Acorda, 2014), Chrono Therapeutics, Velicept Therapeutics and Palyon Medical
Management team
Scientific Advisor
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Board Of Directors
Scientific Advisory Board
Director of Research 1st class at the CNRS, directing the multidisciplinary Chemistry & Biology, Modeling & Immunology for Therapy (CBMIT) team within the CNRS and the Université de Paris
Chief Executive Officer of the Institute for Research in Immunology and Cancer at the University of Montréal
Professor of Target and Systems Biochemistry at the Faculty of Science of the Vrije Universiteit Amsterdam
